E-LIB Suche - Ergebnisse für: Yanuv, Ilan

1

Kidney function loss and albuminuria progression with GLP-1..:

Schechter, Meir ; Melzer Cohen, Cheli ; Fishkin, Alisa...
Cardiovascular Diabetology. 22 (2023) 1 - p. , 2023

2

Long-Term, Real-World Kidney Outcomes with SGLT2i versus DP..:

Melzer Cohen, Cheli ; Schechter, Meir ; Rozenberg, Aliza...
Clinical Journal of the American Society of Nephrology. 18 (2023) 9 - p. 1153-1162 , 2023

Link: https://doi.org/10.2215/..

3

Curalin supplement for patients with type 2 diabetes mellit..:

Weinberg Sibony, Roni ; Wainstein, Julio ; Ish Shalom, Maya...
Diabetes/Metabolism Research and Reviews. 39 (2023) 4 - p. , 2023

Link: https://doi.org/10.1002/..

4

Risk of hospitalization with sodium‐glucose cotransporter‐2..:

Schechter, Meir ; Melzer Cohen, Cheli ; Zelter, Tamir...
Diabetes, Obesity and Metabolism. 25 (2023) 10 - p. 3054-3058 , 2023

Link: https://doi.org/10.1111/..

5

The effect of lifestyle intervention on cardiometabolic ris..:

Tsodikov, Faina ; Schechter, Meir ; Goldsmith, Rebecca...
International Journal of Obesity. 46 (2022) 5 - p. 926-934 , 2022

Link: https://doi.org/10.1038/..

6

Medical cannabis for pain management in patients undergoing..:

Bassat, Orit Kliuk Ben ; Schechter, Meir ; Ashtamker, Natalia...
Clinical Kidney Journal. , 2022

Link: https://doi.org/10.1093/..

7

Epidemiology of the diabetes-cardio-renal spectrum: a cross..:

Schechter, Meir ; Melzer Cohen, Cheli ; Yanuv, Ilan...
Cardiovascular Diabetology. 21 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

8

Cardiorenal outcomes with sodium/glucose cotransporter-2 in..:

Schechter, Meir ; Melzer-Cohen, Cheli ; Rozenberg, Aliza...
Cardiovascular Diabetology. 20 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..

9

Cardiovascular and renal benefits of dapagliflozin in patie..:

Bajaj, Harpreet S. ; Raz, Itamar ; Mosenzon, Ofri...
Diabetes, Obesity and Metabolism. 22 (2020) 7 - p. 1122-1131 , 2020

Link: https://doi.org/10.1111/..

10

Cardiorenal outcomes with dapagliflozin by baseline glucose..:

Cahn, Avivit ; Wiviott, Stephen D. ; Mosenzon, Ofri...
Diabetes, Obesity and Metabolism. 23 (2020) 1 - p. 29-38 , 2020

Link: https://doi.org/10.1111/..

11

Safety of dapagliflozin in a broad population of patients w..:

Cahn, Avivit ; Raz, Itamar ; Bonaca, Marc...
Diabetes, Obesity and Metabolism. 22 (2020) 8 - p. 1357-1368 , 2020

Link: https://doi.org/10.1111/..

12

Hypoglycaemia manifestations and recurrent events: Lessons ..:

Cahn, Avivit ; Mosenzon, Ofri ; Bhatt, Deepak L....
Diabetes, Obesity and Metabolism. 19 (2017) 7 - p. 1045-1050 , 2017

Link: https://doi.org/10.1111/..

13

Long-Term, Real-World Kidney Outcomes with SGLT2i versus DP..:

Melzer Cohen, Cheli ; Schechter, Meir ; Rozenberg, Aliza...
https://research.rug.nl/en/publications/b366eb46-ce26-499d-a6ad-5f9329b24217. , 2023

Link: https://hdl.handle.net/1..

14

Kidney function loss and albuminuria progression with GLP-1..:

Schechter, Meir ; Melzer Cohen, Cheli ; Fishkin, Alisa...
https://research.rug.nl/en/publications/70d3dbbb-b390-4e97-b3e3-a4e7d1433efb. , 2023

Link: https://hdl.handle.net/1..

15

Effects of dapagliflozin on hospitalisations in people with..:

Schechter, Meir ; Wiviott, Stephen D ; Raz, Itamar...
https://research.rug.nl/en/publications/b7f5de5d-93e3-4e6b-9731-c235ff5e4406. , 2023

Link: https://hdl.handle.net/1..